Wednesday, July 26, 2023
HaemaLogiX and Peter MacCallum Cancer Centre have jointly entered into a co-development agreement to conduct the first in human Phase I trial of HaemaLogiX's CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma.
Under the collaborative agreement, HaemaLogiX will contribute its patented KappaMab technology to partner with Peter MacCallum Cancer Centre. Together, they aim to develop and establish a method of manufacturing, and jointly conduct the crucial Phase I trial for KMA.CAR-T in patients with kappa-type multiple myeloma.
This agreement comes after a successful collaborative preclinical research project that provided compelling evidence of the therapy's potential. In the preclinical research, KMA.CAR-T cells were tested against myeloma cell lines expressing the KMA antigen. The results demonstrated that the CAR-T cells specifically targeted and killed the KMA-expressing myeloma cells, indicating a selective and potent anti-myeloma activity of the therapy.
KMA.CAR-T is an innovative immunotherapy designed to treat kappa-type multiple myeloma, a form of cancer that affects plasma cells in the bone marrow. This therapy utilises CAR-T cell technology to target a specific receptor called Kappa Myeloma Antigen (KMA), which is unique to the surface of myeloma cells in patients with kappa-type multiple myeloma.
